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Background: Recently, the cancer stem cell hypothesis has become widely accepted. Cancer stem cells are
thought to possess the ability to undergo self-renewal and differentiation, similar to normal stem cells.
Nucleostemin (NS), initially cloned from rat neural stem cells, binds to various proteins, including p53, in the nucleus
and is thought to be a key molecule for stemness. NS is expressed in various types of cancers; therefore, its role in
cancer pathogenesis is thought to be important. This study was conducted to clarify the clinicopathological and
prognostic impact of NS in invasive breast cancers.
Method: The correlation between NS immunoreactivity and clinicopathological parameters was examined in 220
consecutive surgically resected invasive breast cancer tissue samples by using tissue microarrays. The presence of
nuclear NS and p53 immunoreactivity in 10% or more of cancer cells was considered as a positive result.
Results: Among the 220 patients, 154 were hormone-receptor (HR)-positive, 22 HER2-positive/HR-negative, and 44
HR-negative/HER2-negative. One hundred and forty-two tumors (64.5%) showed NS positivity, and this positivity
was significantly correlated with estrogen receptor (ER) (P = 0.050), human epidermal growth factor receptor 2
(HER2) (P = 0.021), and p53 (P = 0.031) positivity. The patients with NS-positive tumors showed significantly shorter
disease-free survival than those with NS-negative tumors. Furthermore, the patient group with NS- and p53-positive
tumors showed significantly poorer prognosis than other patient groups. Multivariate analysis showed that NS status
was an independent prognostic indicator.
Conclusions: NS may play a significant role in the determination of breast cancer progression in association with p53
alterations. The NS status of patients with luminal and HER2 type breast cancers may be a useful prognostic marker.Background
Breast cancer is one of the most prevalent diseases world-
wide. While most patients with early breast cancers are
cured with surgically resection followed by appropriate ad-
juvant drug and radiation therapy, approximately 30% of
these patients experience relapse and develop metastatic
disease [1]. In this metastatic stage, tumor cells frequently
acquire resistance to various drugs during intensive sys-
temic therapies, and eventually their aggressiveness and
growth become uncontrollable. Less than 5% of patients
with distant metastatic tumors live for 5 years [2].* Correspondence: htsuda@ndmc.ac.jp
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unless otherwise stated.Therefore, identification of potential targets with the
aim of developing interventional drugs is an important
area of research.
The hypothesis that various types of cancers, including
breast cancer, are generated by a limited number of cancer
stem cells has been widely accepted recently [3]. Cancer
stem cells, like normal stem cells, are thought to have
two important characteristics: the ability to undergo self-
renewal and the ability to undergo differentiation into dif-
ferent cell types [4]. Furthermore, these cells are thought
to be inherently resistant to various therapeutic drugs,
making the eradication of tumors containing cancer stem
cells with the use of the current treatment protocols diffi-
cult [5]. To overcome these obstacles, the development of
new therapeutic strategies to target cancer stem cells is
essential for the management of breast cancer.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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maintaining “stemness” [6]. NS was initially cloned from
rat neural stem cells and was found to contain two
GTP-binding motifs and an N-terminal basic domain,
which is essential for binding to p53 [6]. NS accumulates
mainly in the nucleoli and moves to the nucleoplasm
after binding with GTP. Interaction of NS with a multi-
tude of proteins in the nucleoplasm, including p53, may
play a significant role in self-renewal, cell cycle regula-
tion, apoptosis, and cell proliferation [7].
NS is expressed in central nervous system stem cells,
embryonic stem cells, and primitive cells in the bone
marrow and testes [6]. Furthermore, various types of
cancers, including the following, have been reported to
express NS: squamous cell carcinomas of the uterine
cervix; head, neck, esophagus, and renal cell carcinomas;
and prostate cancer [8-13]. Moreover, recent evidence
indicates that NS is involved in maintaining cancer stem
cells [14,15]. These findings suggest that NS may also
play an important role in cancer pathogenesis as well as
in cancer stem cell maintenance. However, no clinical
study has investigated the role of NS in breast cancer.
If NS is expressed in breast cancer stem cells and its ex-
pression is correlated with disease progression in breast
cancer, it may serve as a powerful prognostic marker for
clinical use. To test this hypothesis, we investigated the ex-
pression of NS in surgically resected invasive breast cancer
specimens from 220 patients by using immunohistochem-
istry. Furthermore, we examined the prognostic implica-
tion of the combination status of NS and p53 and the
significance of NS expression status among the three bio-
logical subtypes of breast tumors: (a) hormone-receptor
(HR) positive (luminal type); (b) human epidermal growth
factor receptor 2 (HER2) positive (HER2 type); and (c) HR
negative and HER2 negative (triple negative).
Methods
Patients and tumor specimens
The patient cohort used in the present study was the
same as the cohort reported in our previous study [16].
Briefly, formalin-fixed paraffin-embedded tissue blocks
of invasive breast cancer specimens from 220 consecu-
tive patients were used to construct tissue microarrays
(TMAs). All patients with unilateral invasive breast car-
cinoma underwent mastectomy or breast-conserving
surgery at the National Defense Medical College (NDMC)
Hospital, Tokorozawa, Japan from 1995 through 1999.
These patients had a median follow-up of 74 months after
surgery (range, 1–151 months), during which 58 patients
experienced relapse. Of the 220 patients, 218 were female
patients and 2 were male patients; 101 (45.9%) patients
had lymph node metastasis and 8 (3.6%) had distant me-
tastasis at the time of breast cancer diagnosis. In most
cases, patients with hormone receptor-positive tumors atthe time of diagnosis were prescribed adjuvant endocrine
therapy (e.g., tamoxifen, toremifene, fadrozole, or LHRH
analogues) for two or more years. The patients with a
large tumor and/or four or more lymph node metastases




and oral fluoropyrimidines. Detailed patient and dis-
ease characteristics are documented in Table 1. Clinico-
pathological data were retrospectively obtained from
medical records [16].
This study was approved by the Medical Ethical
Committee of National Defense Medical College and by
the Institutional Review Board of National Cancer Center.
Tissue microarray construction
We constructed TMA blocks as previously described [16].
Briefly, double tissue cores with a diameter of 2 mm were
obtained from each donor block, and these core speci-
mens were transferred to a recipient block using a Tissue
Microarrayer (Beecher Instruments, Silver Spring, MD,
USA). One TMA block contained a maximum of 26
tumor samples, and 13 TMA sets were used in this study.
Immunohistochemistry
Immunohistochemistry was performed on TMA sections
of 220 patients. The antibodies used were mouse mono-
clonal anti-human NS (clone BL2858; Bethyl Laborator-
ies, Inc., Montgomery, TX, USA) and mouse monoclonal
anti-human p53 (clone DO-7; Dako, Carpinteria, CA,
USA). Formalin-fixed paraffin-embedded specimens on
the TMA were cut into 4 μm-thick sections. The tissue
sections were deparaffinized twice in xylene for 10 min
and rehydrated through graded ethanol (99%, 90%, 80%,
and 70%) to water. Antigens were retrieved by micro-
wave heating for 30 min in 10 mM sodium citrate
(pH 6.0) for NS and by autoclaving for 15 min in
10 mM Tris–HCl (pH 9.0) for p53. To block endogen-
ous peroxidase activity, the sections were treated with
100% methanol containing 3% hydrogen peroxide for
5 min. Non-specific binding was blocked by incubation
in 2% normal swine serum (Dako) in phosphate-buffered
saline. The slides were incubated with primary anti-
bodies at 4°C overnight and then reacted with a dextran
polymer reagent combined with secondary antibodies
and peroxidase (Envision Plus; Dako) for 30 min at room
temperature. Specific antigen–antibody reactions were
visualized with 0.2% diaminobenzidine tetrahydrochlo-
ride and hydrogen peroxide. Counterstaining was per-
formed using Mayer’s hematoxylin. A separate assay was
run using a case of esophageal carcinoma as a positive
control for NS [17]. Reactions without the primary anti-
bodies were used as negative controls.
Table 1 Correlation between nucleostemin expression
and clinicopathological variables in surgically resected
breast cancers
Variable Number of cases (%)
Nucleostemin expression
Total Positive Negative P-value
(n = 220) (n = 142) (n = 78)
Age
Median (range) 52 (30 ~ 82 y)
≦52 109 71 (65) 38 0.89
>52 111 71 (64) 40
Tumor size
<5.0 cm 174 108 (62) 66 0.21
≧5.0 cm 42 31 (74) 11
Unknown 4 4(100) 0
Lymph node metastasis
Negative 115 70 (61) 45 0.39
Positive 101 68 (67) 33
Unknown 4 4 (100) 0
Distant metastasis
Negative 209 134 (64) 75 0.72
Positive 8 6 (75) 2
Unknown 3 2 (67) 1
Stage
I or II 179 111 (61) 68 0.13
III or IV 37 28 (76) 9
Unknown 4 3 (75) 1
Nuclear grade
1, 2 137 86 (63) 51 0.48
3 83 56 (67) 27
ER status
Negative 88 50 (57) 38 0.050
Positive 132 92 (70) 40
PgR status
Negative 96 57 (59) 39 0.16
Positive 124 85 (69) 39
HR (ER/PgR) status
Negative 66 40 (61) 26 0.42
Positive 154 102 (66) 52
HER2 status
Negative 190 117 (62) 73 0.02
Positive 30 25 (83) 5
p53 status
Negative 143 85 (59) 58 0.03
Positive 77 57 (74) 20
Table 1 Correlation between nucleostemin expression
and clinicopathological variables in surgically resected
breast cancers (Continued)
Histological type
Ductal 191 125 (65) 66 0.38
Lobular 10 5 (50) 5
Mucinous 6 6 (100) 0
Tubular 5 1 (20) 4
Medullary 3 2 (67) 1
Other 5 3 (60) 2
Abbreviation: ER Estrogen receptor, PgR Progesterone receptor, HR Hormone
receptor.
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proportion of nuclear staining area. Specimens with 10%
or more immunoreactive tumor cells were considered
positive, and those with less than 10% were considered
negative. Immunohistochemistry results were indepen-
dently evaluated by two observers (T.K. and H.T.), and
cases with discrepant grades were re-evaluated by dis-
cussion until consensus was achieved.
ER, PgR, and HER2 had already been immunohisto-
chemically re-assessed on new sections in our previous
study [16] by using mouse monoclonal anti-human ER
(clone 1D5, Dako), mouse anti-human PgR (clone PgR636,
DAKO), and rabbit polyclonal anti-HER2 antibody
(HercepTest kit, Dako) according to the methods recom-
mended by the manufacturer. ER and PgR were consid-
ered positive if the nuclear staining was observed in 10%
or more of tumor cells. Samples were considered hormone
receptor positive if they were ER and/or PgR positive and
hormone receptor negative if they were ER and PgR nega-
tive. HER2 results were considered positive if the IHC
score was “3+” or gene amplification was detected by FISH
according to the 2007 ASCO/CAP guideline [18].
Statistical analysis
Comparisons between groups were evaluated using chi-
squared test or Fisher’s exact test. Disease-free sur-
vival (DFS) curves of patients were drawn using the
Kaplan-Meier method and compared using the log-rank
test. Cox multivariate proportional hazards models were
used to explore the association of variables with DFS. For
all tests, P < 0.05 was considered to be statistically signifi-
cant. All analyses were performed using the software JMP
6.0 for Windows (SAS Institute Inc., Cary, NC, USA).
Results
Clinicopathological and prognostic implications of NS
expression for the entire patient cohort
Initially, the expression levels of NS were classified as nega-
tive (0%), weak (1% to <10%), moderate (10% to <30%), or
strong (30% or more). The number of cases categorized
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62, 16, 55, and 87, respectively. From these results, we
judged that NS expression showed bimodal distribution
and used a 10% threshold for NS positivity between nega-
tive and positive groups.
NS protein was frequently detected in the nucleus of
breast cancer cells. Although strong immunoreaction
was observed in both the nucleoli and nucleoplasm of
cancer cells (Figure 1A), nuclear immunoreaction of NS
in some cases was limited to the nucleoli of cancer cells
(Figure 1B). Such cells were also judged as positive for
NS immunoreactivity. Cytoplasmic staining was not ob-
served. These findings are consistent with those of previ-
ous reports [6,17,19]. We found that 78 (35.5%) or 142
(64.5%) patients had NS-negative or NS-positive tumors,
respectively (Figure 1C). Unremarkable mammary glands
showed nuclear NS immunoreactivity in almost all lu-
minal epithelial cells (Figure 1D).
Tumors with NS positivity showed a higher frequency
of ER positivity, HER2 positivity, and p53 positivity
(P = 0.050, P = 0.021, and P = 0.031, respectively), whereas
NS expression status was not correlated with tumor size,
lymph node metastasis, distant metastasis, tumor nu-
clear grade, or PgR positivity. NS expression was de-
tected at 50% or more in all histological types studied
except tubular carcinoma (20%), and the positive rate
was 100% (6 of 6) in mucinous carcinoma. Patients with
NS-positive tumors showed significantly shorter DFSA
C
Figure 1 Nucleostemin (NS) expression in human breast cancer tissue
activity in both nucleoli and nucleoplasm. B. Another NS-positive tumor, N
cancer cells are also judged as NS-positive. This case was also classified as N
gland shows nuclear NS immunoreactivity in almost all luminal epithelial ctime than those with NS-negative tumors (P = 0.020,
Figure 2).
Prognostic implication of the NS and p53 combination
status for the entire patient cohort
Since it has been reported that physical and functional
interaction between NS and p53 appear to be essential
for self-renewal, cell cycle regulation, cell proliferation,
and apoptosis [7], we next examined the prognostic im-
plication of the combination status of NS and p53 for
the entire patient cohort. We found that 143 (65%) and
77 (35%) patients had p53-negative and p53-positive tu-
mors, respectively. The patients with p53-positive tu-
mors showed significantly shorter DFS time than those
with p53-negative tumors (P = 0.006, Figure 3A).
A striking stratification of relapse risk was identified
when three different combinations of NS and p53
status were evaluated: 57 cases with a combination of
NS-positive/p53-positive tumors (unfavorable group); 105
cases comprising 20 NS-negative/p53-positive tumors and
85 NS-positive/p53-negative tumors (intermediate group);
and 58 cases with NS-negative/p53-negative tumors
(favorable group). The unfavorable group had a 5-year
DFS rate of 55%, compared with 75% in the intermediate
group and 86% in the favorable group (Figure 3B). The un-
favorable group had significantly shorter DFS time than
the intermediate and favorable groups (log-rank test
P = 0.034 and P = 0.0007, respectively).B
D
s. A. A NS-positive tumor. Almost all cancer cells show NS immunore-
S immunoreactivity is limited to nucleoli in nuclei of cancer cells. Such
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Figure 2 Prognostic impact of NS status in the patients with
primary breast cancer. This figure shows disease-free survival (DFS)
curves for the 142 patients with NS-positive tumors and for the
78 patients with NS-negative tumors. These two curves differ
significantly (P = 0.020).
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Figure 3 Prognostic impact of the combination status of NS and p53
(DFS) curves for the 77 patients with p53-positive tumors and for the 143 p
(P = 0.006). B. This figure shows three disease-free survival (DFS) curves: for
group’), for 105 patients comprising 20 NS-negative and p53-positive tumo
and for 58 patients with NS-negative and p53-negative tumors (‘favorable’
the intermediate group or the favorable group (log-rank test P = 0.034 and
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subtypes of breast tumors
Currently, treatment strategies differ between the bio-
logical subtypes of breast tumors; therefore, we exam-
ined the prognostic implication of NS among three
groups of patients divided based on their biological sub-
type: 154 patients with luminal-type tumors (HR-posi-
tive); 22 patients with HER2-type tumors (HER2-positive
and HR-negative); and 44 patients with triple-negative
tumors (HR and HER2-negative). Eight patients with
HR-positive and HER2-positive tumors were included
and analyzed as luminal-type patients.
Among the patients with luminal-type tumors, pa-
tients with NS-positive tumors showed a significantly
shorter DFS time than those with NS-negative tumors
(P = 0.033, Figure 4A). Among the patients with HER2-
positive tumors, patients with NS-positive tumors had a
5-year DFS rate of 28% compared with 100% in patients
with NS-negative tumors (Figure 4B). However, the
P-value was not calculated because there was no relapseble’ (n = 58)
 + Negative p53)
)
Positive NS + Negative p53
or  




 (n = 143)
P = 0.006)
in the patients with primary breast cancer. A. Disease-free survival
atients with p53-negative tumors. These two curves differ significantly
the 57 patients with NS-positive and p53-positive tumors (‘unfavorable
rs and 85 NS-positive and p53-negative tumors (‘intermediate’ group),
group). The unfavorable group has significantly shorter DFS time than
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Figure 4 Prognostic impact of NS status in the three subgroups
of the different biological subtype tumors: luminal-type
tumors, HER2-type tumors, and triple-negative tumors.
A. Subgroup analysis of the 154 patients with luminal-type tumors
(HR-positive tumors). Two disease-free survival (DFS) curves, that for
the 102 patients with NS-positive tumors and that for the 52 patients
with NS negative tumors, differ significantly (P = 0.033). B. Subgroup
analysis of the 22 patients with HER2-type tumors (HER2-positive
and HR-negative tumors). In two disease-free survival (DFS) curves,
that for the 18 patients with NS-positive tumors and that for the 4
patients with NS-negative tumors, five-year DFS rates differ largely
(100% vs 28%). P-value was not available because there was no
relapse in the patients with NS-negative tumors. C. Subgroup
analysis of the 44 patients with triple-negative tumors (HR and HER2
negative tumors). The two curves do not differ significantly (P = 0.41).
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the patients with triple-negative tumors, there was no
difference between the survival curves for patients with
NS-positive tumors and those with NS-negative tumors
(P = 0.41, Figure 4C).
Multivariate analysis of prognostic factors and evaluation
of NS
Univariate analysis showed that HR, HER2, nuclear
grade, tumor size, nodal status, distant metastasis, and
NS expression were significantly correlated with DFS.
When multivariate analysis was performed using these
seven factors, NS expression status was selected as an
independent prognostic factor (P = 0.036), together with
nuclear grade, tumor size, lymph node status, and distant
metastatic status (P = 0.0008, 0.0007, 0.0038 and <0.0001,
respectively; Table 2).
Discussion
In the present cohort, we found that the NS protein ex-
pression status was positively correlated with both ER
and HER2 status and was a powerful prognostic factor.
Patients with NS-positive breast tumors had a signifi-
cantly shorter DFS time than those with NS-negative tu-
mors (P = 0.020, Figure 2), and multivariate analysis for
DFS showed that NS positivity had an independent im-
pact as a prognostic indicator among breast cancer pa-
tients (P = 0.036, Table 2). To our knowledge, this is the
first report to show the clinical implication of NS pro-
tein expression in invasive breast cancers.
Although several studies have shown the important
roles of NS in the pathogenesis of various cancer types
[8-13] as well as the maintenance of cancer stem cells
[14,15], no direct evidence is yet available to support
that NS is a marker of cancer stem cells. Currently, mo-
lecules such as CD44, CD133, ALDH1, and CXCR4 have
been found to be potential markers of cancer stem cells
[20-25]. Furthermore, the expression of these stem cell
markers has been shown to be a poor prognostic
Table 2 Prognostic impacts of clinicopathological variables computed by Cox’s univariate and multivariate analyses in
patients with primary breast cancer
Univariate Multivariate
















Positive 2.91 (1.59-5.34) 1.65 (0.80-3.41)




3 3.30 (1.94-5.64) 2.97 (1.57-5.61)




>5.0 cm 6.89 (3.97-11.9) 2.99 (1.59-5.66)




Positive 4.51 (2.45-8.31) 2.73 (1.38-5.38)




Positive 71.6 (26.1-196.5) 62.3 (15.5-251.1)
Abbreviation: 95% CI 95% confidence interval.
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Based on these observations, our results show that high
NS expression is a powerful indicator of poor outcome,
consistent with the idea that NS may be a breast cancer
stem cell marker.
The limitations of the present study included the
retrospective analyses and the heterogeneity of adjuvant
treatments. Therefore, one should pay careful attention
when interpreting these results. Further studies using a
uniformly treated patient cohort are required to clarify
the role of NS in breast cancer stem cells.
We found that the patient group with tumors coex-
pressing NS and p53 had shorter DFS times than the pa-
tient group with tumors negative for either NS or p53.
GTP binding modulates the movement of NS from the
nucleoli to the nucleoplasm; NS then binds p53 at its
N-terminal basic domain, which results in the suppres-
sion of p53 function [6,7]. Because prolongation of the
half-life of most of the mutated p53 protein induces its
nuclear accumulation, it is generally believed that the
p53 pathway does not fully function in tumors with high
p53 nuclear immunoreactivity [31-33]. This evidence
leads to the assumption that p53 function would be pro-
foundly suppressed in tumors coexpressing NS and p53.
Our results show the validity of this concept and that
functional crosstalk between NS and p53 may also occur
in vivo.
Currently, we cannot explain the correlation between
NS expression and p53 expression. Although several
studies have shown that NS modulates the expression ofwild-type p53 [34,35], the role of NS in breast cancers
with mutant p53 has not yet been evaluated. Further re-
search is needed to elucidate the correlation.
We found that the NS expression status was positively
correlated with both ER and HER2 status and also found
a significant prognostic implication of NS expression
for patients with luminal-type tumors and those with
HER2-type tumors, except for those with triple-negative
tumors. NS was first identified as a gene upregulated in
MCF-7 cells upon 17β-estradiol treatment [36]; there-
fore, our inclusion of subgroup analysis among patients
with luminal-type tumors was reasonable. To our know-
ledge, this is the first report to demonstrate the possible
association between NS and HER2. Zhang G et al.
showed that NS is required for the expression of EGF
and EGFR in an esophageal squamous carcinoma cell
line [13]. Presumably, NS is required for the expression
of HER2 in a manner similar to that for EGFR. We
found no survival impact of the NS expression status
among patients with triple-negative tumors, who show
higher rates of mutated p53 than patients with luminal-
type or HER2-type tumors [37]. NS can function in the
presence of wide-type p53 [7]; therefore, the expression
status of NS may have survival impact only for the
luminal-type and HER2-type tumors.
Conclusions
In summary, our results indicate that the expression sta-
tus of NS, abundant in stem cells, is a prognostic indica-
tor in breast cancer patients, especially for those with
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expression of NS and p53 correlates with poorer prog-
nostic outcomes. Examination of NS expression may be
useful for the stratification and management of breast
cancer patients in future daily practice.
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